MD20160131A2 - Compus de tiacumicină şi regim de tratament asociat - Google Patents
Compus de tiacumicină şi regim de tratament asociat Download PDFInfo
- Publication number
- MD20160131A2 MD20160131A2 MDA20160131A MD20160131A MD20160131A2 MD 20160131 A2 MD20160131 A2 MD 20160131A2 MD A20160131 A MDA20160131 A MD A20160131A MD 20160131 A MD20160131 A MD 20160131A MD 20160131 A2 MD20160131 A2 MD 20160131A2
- Authority
- MD
- Moldova
- Prior art keywords
- compound
- days
- administration
- thiacumycin
- clostridium difficile
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Se propune un compus al tiacumicinei, un stereoizomer al acesteia, un polimorf al acesteia sau un solvat farmaceutic acceptabil al acesteia şi o compoziţie farmaceutică, ce conţine un compus al tiacumicinei, un stereoizomer al acesteia, un polimorf al acesteia sau un solvat farmaceutic acceptabil al acesteia utilizate în tratamentul oral al infecţiilor provocate de Clostridium difficile (CDI) sau diareii, sau bolii asociate cu Clostridium difficile (CDAD) la pacient în conformitate cu un regim de dozare selectat din grupul ce constă din: i - administrarea a 200 mg de compus tiacumicinic BID, timp de 5 zile, urmate de 5 zile de repaos, apoi 200 mg odată pe zi pentru următoarele 10 zile şi ii - administrarea a 200 mg de compus tiacumicinic BID, timp de 5 zile, urmate de administrarea unei singure doze de 200 mg peste o zi, timp de 20 de zile.De asemenea, se propune o metodă de restabilire a populaţiei de bifidobacterii din intestin la pacientul care suferă de infecţii provocate de Clostridium difficile (CDI) sau diaree, sau boli asociate cu Clostridium difficile (CDAD) şi care primeşte tratament oral cu un compus al tiacumicinei, de la 50% până la 90% din populaţia de bifidobacterii din intestin cu administrarea compusului tiacumicinic, timp de 15...45 de zile de la începutul tratamentului, prin administrarea orală a compusului tiacumicinic la pacient în conformitate cu regimul de dozare, care este selectat din grupul menţionat mai sus.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14075031 | 2014-05-09 | ||
| PCT/EP2015/000965 WO2015169451A1 (en) | 2014-05-09 | 2015-05-11 | Treatment regimen tiacumicin compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MD20160131A2 true MD20160131A2 (ro) | 2017-05-31 |
| MD4695B1 MD4695B1 (ro) | 2020-05-31 |
| MD4695C1 MD4695C1 (ro) | 2021-02-28 |
Family
ID=50771031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20160131A MD4695C1 (ro) | 2014-05-09 | 2015-05-11 | Compus tiacumicinic şi regim de tratament asociat |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10137141B2 (ro) |
| EP (1) | EP3139932B1 (ro) |
| JP (1) | JP6579662B2 (ro) |
| KR (1) | KR20160149288A (ro) |
| AU (1) | AU2015258130B2 (ro) |
| CA (1) | CA2948400A1 (ro) |
| CY (1) | CY1120847T1 (ro) |
| DK (1) | DK3139932T3 (ro) |
| EA (1) | EA031756B1 (ro) |
| ES (1) | ES2694028T3 (ro) |
| GE (2) | GEP20186872B (ro) |
| HR (1) | HRP20181756T1 (ro) |
| IL (1) | IL248782B (ro) |
| LT (1) | LT3139932T (ro) |
| MA (1) | MA39952B1 (ro) |
| MD (1) | MD4695C1 (ro) |
| PL (1) | PL3139932T3 (ro) |
| PT (1) | PT3139932T (ro) |
| RS (1) | RS57994B1 (ro) |
| SI (1) | SI3139932T1 (ro) |
| TR (1) | TR201815891T4 (ro) |
| UA (1) | UA122203C2 (ro) |
| WO (1) | WO2015169451A1 (ro) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016289307A1 (en) * | 2015-07-03 | 2018-01-18 | Astellas Pharma Europe Ltd. | Novel dosage regimen tiacumicin compound |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4918174A (en) | 1986-09-26 | 1990-04-17 | Abbott Laboratories | Tiacumicin compounds |
| US5583115A (en) | 1995-05-09 | 1996-12-10 | Abbott Laboratories | Dialkyltiacumicin compounds |
| US5767096A (en) | 1996-07-12 | 1998-06-16 | Abbott Laboratories | Bromotiacumicin compounds |
| JP2005534332A (ja) | 2002-07-29 | 2005-11-17 | オプティマー ファーマシューティカルズ、インコーポレイテッド | チアクマイシン生産 |
| WO2006085838A1 (en) | 2005-01-31 | 2006-08-17 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
| PT2305245T (pt) * | 2004-05-14 | 2019-03-19 | Merck Sharp & Dohme | Tratamento de doenças associadas com a utilização de antibióticos |
| US7378508B2 (en) | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
| US20080176927A1 (en) * | 2007-01-19 | 2008-07-24 | Optimer Pharmaceuticals, Inc. | Compositions of stable tiacumicins |
| CN102030791B (zh) | 2010-10-28 | 2013-01-23 | 中国科学院南海海洋研究所 | 四种台勾霉素类化合物及其制备方法和在制备抗菌药物中的应用 |
| CN102115757B (zh) | 2010-12-14 | 2015-10-28 | 中国科学院南海海洋研究所 | 台勾霉素的生物合成基因簇及其应用 |
| US20150157653A1 (en) | 2012-03-16 | 2015-06-11 | Optimer Pharmaceuticals, Inc. | Prevention of Clostridium Difficile Infection in High Risk Patients |
| JO3464B1 (ar) | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | التركيبات الخاصة بمركبات التياكوميسين |
-
2015
- 2015-05-11 EP EP15731245.5A patent/EP3139932B1/en active Active
- 2015-05-11 LT LTEP15731245.5T patent/LT3139932T/lt unknown
- 2015-05-11 CA CA2948400A patent/CA2948400A1/en not_active Abandoned
- 2015-05-11 SI SI201530443T patent/SI3139932T1/sl unknown
- 2015-05-11 RS RS20181271A patent/RS57994B1/sr unknown
- 2015-05-11 GE GEAP201514327A patent/GEP20186872B/en unknown
- 2015-05-11 PL PL15731245T patent/PL3139932T3/pl unknown
- 2015-05-11 HR HRP20181756TT patent/HRP20181756T1/hr unknown
- 2015-05-11 UA UAA201610790A patent/UA122203C2/uk unknown
- 2015-05-11 PT PT15731245T patent/PT3139932T/pt unknown
- 2015-05-11 GE GEAP201814327A patent/GEAP201814327A/en unknown
- 2015-05-11 MA MA39952A patent/MA39952B1/fr unknown
- 2015-05-11 JP JP2016567190A patent/JP6579662B2/ja active Active
- 2015-05-11 EA EA201692107A patent/EA031756B1/ru unknown
- 2015-05-11 KR KR1020167034087A patent/KR20160149288A/ko not_active Ceased
- 2015-05-11 ES ES15731245.5T patent/ES2694028T3/es active Active
- 2015-05-11 AU AU2015258130A patent/AU2015258130B2/en not_active Ceased
- 2015-05-11 US US15/309,992 patent/US10137141B2/en not_active Expired - Fee Related
- 2015-05-11 WO PCT/EP2015/000965 patent/WO2015169451A1/en not_active Ceased
- 2015-05-11 TR TR2018/15891T patent/TR201815891T4/tr unknown
- 2015-05-11 DK DK15731245.5T patent/DK3139932T3/en active
- 2015-05-11 MD MDA20160131A patent/MD4695C1/ro active IP Right Grant
-
2016
- 2016-11-06 IL IL248782A patent/IL248782B/en active IP Right Grant
-
2018
- 2018-10-30 CY CY181101119T patent/CY1120847T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL248782B (en) | 2020-08-31 |
| TR201815891T4 (tr) | 2018-11-21 |
| IL248782A0 (en) | 2017-01-31 |
| KR20160149288A (ko) | 2016-12-27 |
| CY1120847T1 (el) | 2019-12-11 |
| JP6579662B2 (ja) | 2019-09-25 |
| LT3139932T (lt) | 2018-11-12 |
| RS57994B1 (sr) | 2019-01-31 |
| AU2015258130A1 (en) | 2016-12-15 |
| WO2015169451A1 (en) | 2015-11-12 |
| DK3139932T3 (en) | 2018-11-12 |
| PL3139932T3 (pl) | 2019-02-28 |
| SI3139932T1 (sl) | 2018-12-31 |
| PT3139932T (pt) | 2018-11-14 |
| ES2694028T3 (es) | 2018-12-17 |
| MD4695B1 (ro) | 2020-05-31 |
| US20170143750A1 (en) | 2017-05-25 |
| EP3139932A1 (en) | 2017-03-15 |
| HRP20181756T1 (hr) | 2018-12-28 |
| JP2017514880A (ja) | 2017-06-08 |
| GEAP201814327A (en) | 2018-02-26 |
| MA39952B1 (fr) | 2018-12-31 |
| EA031756B1 (ru) | 2019-02-28 |
| MA39952A (fr) | 2017-03-15 |
| UA122203C2 (uk) | 2020-10-12 |
| MD4695C1 (ro) | 2021-02-28 |
| US10137141B2 (en) | 2018-11-27 |
| CA2948400A1 (en) | 2015-11-12 |
| EP3139932B1 (en) | 2018-08-01 |
| GEP20186872B (en) | 2018-06-25 |
| AU2015258130B2 (en) | 2019-10-31 |
| EA201692107A1 (ru) | 2017-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| MX344787B (es) | Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara. | |
| JP2015038135A5 (ro) | ||
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| RU2018103081A (ru) | Способы лечения колитов | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| BR112018068784A2 (pt) | método para o tratamento de leucemia | |
| MX2021008536A (es) | Formulaciones en comprimidos de liberacion modificada que contienen inhibidores de fosfodiesterasa. | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| JP2016505050A5 (ro) | ||
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| MX2023002649A (es) | Nueva formulacion de acido gamma-aminobutirico. | |
| MD20160131A2 (ro) | Compus de tiacumicină şi regim de tratament asociat | |
| EA201890929A1 (ru) | Низкие дозировки композиций дипиридамола для перорального приема и их использование | |
| TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
| EA201890101A1 (ru) | Новая схема лечения тиакумициновым соединением | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| RU2013126798A (ru) | Комбинированная терапия дексаметазоном | |
| EA201992690A1 (ru) | Применение вибегрона для лечения гиперактивного мочевого пузыря | |
| EA202090842A1 (ru) | Таблетки деферипрона с отсроченным высвобождением и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued | ||
| PD4A | Change of proprietorship (patent for invention) |
Owner name: TILLOTTS PHARMA AG, CH Free format text: PREVIOUS PROPRIETOR: ASTELLAS PHARMA EUROPE LTD, GB STR. 2000 HILLSWOOD DRIVE CHERTSEY, SURREY KT16 0RS, REGATUL UNIT, MAREA BRITANIE |